Articles

It is well-recognized that radiation-induced symptoms can be extremely severe for patients with head and neck cancer. Although “magic mouthwash” (ie, diphenhydramine plus lidocaine plus antacid [DLA]) is frequently used for the treatment of oral mucositis associated with radiotherapy to the head and neck, until now there has been no solid evidence for this approach. Read More ›

In the United States, the 3.1 million registered nurses (RNs) account for the largest health profession, and this is projected to grow by 33% by 2025 (from 2012). Read More ›

Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene–based assay was used to guide treatment decision­-making, according to new data presented at the 2016 American Association for Cancer Research meeting.

Read More ›

SGX942, a novel agent that is first in its class, decreased the incidence of severe oral mucositis in patients with head and neck cancer undergoing chemoradiation, according to new research. Read More ›

At the 2016 Palliative Care in Oncology Symposium, the message was clear and emphatic: caregivers should be viewed as both co-deliverers and co-recipients of healthcare services. Read More ›

Patients with cervical and endometrial cancers experience fewer gastrointestinal and genitourinary adverse events and have improved quality of life when they receive intensity-modulated radiation therapy (IMRT) compared with conventional radiation therapy. Read More ›

Delirium is an exceedingly prevalent syndrome among patients with cancer, but is underrecognized and undertreated. Read More ›

Many patients with advanced melanoma or advanced lung cancer have benefited from treatment with checkpoint inhibitors, which have helped extend survival to previously unthinkable lengths. Read More ›

Nausea is part of a symptom cluster associated with chemotherapy, but the experience of nausea may be a symptom cluster in and of itself. Read More ›

A novel compound called CPX-351 that combines 2 older drugs (cytarabine and daunorubicin) in a new drug-delivery platform improved survival among older patients with newly diagnosed, high-risk (secondary) acute myeloid leukemia (AML). Read More ›